Sawyer & Company Inc Sells 79 Shares of Cigna Corp (NYSE:CI)
Sawyer & Company Inc lessened its stake in shares of Cigna Corp (NYSE:CI) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,957 shares of the health services provider’s stock after selling 79 shares during the period. Sawyer & Company Inc’s holdings in Cigna were worth $1,254,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Lowe Wealth Advisors LLC acquired a new stake in Cigna during the first quarter worth $34,000. Truvestments Capital LLC bought a new position in shares of Cigna during the first quarter valued at $37,000. Lavaca Capital LLC bought a new position in shares of Cigna during the first quarter valued at $40,000. C J Advisory Inc bought a new position in shares of Cigna during the first quarter valued at $40,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Cigna during the first quarter valued at $49,000. Institutional investors own 88.11% of the company’s stock.
NYSE:CI traded up $3.84 on Monday, hitting $171.14. 62,187 shares of the stock were exchanged, compared to its average volume of 2,037,262. The firm has a market capitalization of $64.10 billion, a PE ratio of 12.03, a price-to-earnings-growth ratio of 0.87 and a beta of 0.71. Cigna Corp has a 52 week low of $141.95 and a 52 week high of $226.60. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.89. The business has a 50-day moving average of $164.54.
A number of research analysts have issued reports on CI shares. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $23.00 to $24.00 in a report on Monday, June 3rd. UBS Group set a $36.00 price objective on Halliburton and gave the company a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. ValuEngine raised Worldline from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Finally, Goldman Sachs Group raised Puxin from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $51.00 to $56.00 in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $217.40.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Further Reading: Cost of Goods Sold (COGS)
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.